source
- TRex Bio and Retension Pharma announce plans for IPOs, outlining biotech pipeline fundingBiotech companies Retension Pharmaceuticals and TRex Bio have filed with the SEC indicating they intend to go public this year, adding to the current wave of biotech IPOs. TRex Bio said it will us…
- FDA’s new CBER and CDER heads back adaptive framework for rare disease therapiesNewly appointed permanent directors of FDA’s CBER and CDER, Karim Mikhail and Michael Davis, indicated they will continue the agency’s push for an adaptive regulatory framework aimed at rare diseas…